Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims

• Published in: Epidemiology and infection Vol. 145; no. 10; pp. 2109 - 2121
• Main Authors: BUCK, P. O., MEYERS, J. L., GORDON, L.-D., PARIKH, R., KUROSKY, S. K., DAVIS, K. L.
• Format: Journal Article
• Language: English
• Published: Cambridge, UK Cambridge University Press 01.07.2017
• Subjects: Administrative Claims, Healthcare - statistics & numerical data; Adolescent; Adolescents; Adult; Adults; Aged; Aged, 80 and over; Asthma; Asthma - economics; Asthma - epidemiology; Asthma - etiology; Child; Childhood infections; Chronic obstructive pulmonary disease; Cohort Studies; Cost engineering; Costs; Diphtheria; Disease control; Economic analysis; Female; Health Care Costs - statistics & numerical data; Humans; Incidence; Lung diseases; Male; Middle Aged; Obstructive lung disease; Original Papers; Patients; Pertussis; Pulmonary Disease, Chronic Obstructive - economics; Pulmonary Disease, Chronic Obstructive - epidemiology; Pulmonary Disease, Chronic Obstructive - etiology; Regression analysis; Respiratory diseases; Retrospective Studies; Teenagers; Tetanus; United States - epidemiology; Vaccination; Vaccines; Young Adult; United States > US; retrospective database analysis; economic burden; pertussis; Asthma; chronic obstructive pulmonary disease
• ISSN: 0950-2688; 1469-4409
• DOI: 10.1017/S0950268817000887

Individuals with chronic respiratory conditions may be at increased risk for pertussis. We conducted a retrospective administrative claims analysis to examine the incidence and economic burden of diagnosed pertussis among adolescents and adults in the USA with chronic obstructive pulmonary disease (COPD) or asthma. Patients aged ⩾11 years with diagnosed pertussis and pre-existing COPD (n = 343) or asthma (n = 1041) were matched 1:1 to patients with diagnosed pertussis but without COPD or asthma. Differences in all-cause costs (‘excess’ costs) during the 45-day and 3-month and 6-month periods before and after the pertussis index date were calculated; adjusted excess costs were estimated via multivariate regressions. The incidence of diagnosed pertussis was higher among patients with COPD or asthma than among matched patients. Compared with matched patients, patients with pertussis and pre-existing COPD or asthma accrued greater all-cause adjusted costs across study periods ($3694 and $1193 more, respectively, in the 45-day period; $4173 and $1301 more in the 3-month period; and $6154 and $1639 more in the 6-month period; all P < 0·0001). Patients with pre-existing COPD or asthma experience an increased economic burden after diagnosed pertussis and may especially benefit from targeted tetanus, diphtheria, and acellular pertussis vaccination strategies.